Eylea Adverse Reactions

Summary of the safety profile: Serious adverse reactions related to the injection procedure have occurred in less than 1 in 2,400 intravitreal injections with Aflibercept (Eylea) and included endophthalmitis, retinal detachment, cataract traumatic, cataract, vitreous detachment and intraocular pressure increased (see Precautions).
The most frequently observed adverse reactions (in at least 5% of patients treated with Aflibercept (Eylea)) were conjunctival hemorrhage, eye pain, intraocular pressure increased, vitreous detachment, vitreous floaters and cataract.
Tabulated list of adverse reactions: The safety data described below include all adverse reactions from eight phase III studies with a reasonable possibility of causality to the injection procedure or medicinal product.
The adverse reactions are listed by system organ class and frequency using the following convention: Very common (≥1/10), common (1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000).
Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. (See table.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Arterial thromboembolic events: Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of ATEs following intravitreal use of VEGF inhibitors.
Immunogenicity: As with all therapeutic proteins, there is a potential for immunogenicity with Aflibercept (Eylea).